What is insulin resistance?
Insulin resistance means muscle, fat and liver cells respond less effectively to insulin — the hormone that normally signals them to take up glucose from the blood. To compensate, the pancreas produces more insulin than usual to keep blood glucose in range, a state called hyperinsulinemia. For a while, this compensation works and blood glucose stays normal, which is exactly why insulin resistance is often described as silent: standard blood sugar tests can look fine for years while the underlying resistance is already building.
If the pancreas eventually can't keep compensating, blood glucose starts to rise — first into the prediabetes range, and in a subset of people, eventually into type 2 diabetes.
How does insulin resistance develop?
Several contributors act independently and interact with each other: excess visceral (abdominal) fat, physical inactivity, chronic low-grade inflammation, poor sleep, genetics and aging. Visceral fat plays an outsized role — it releases free fatty acids and inflammatory signaling molecules that interfere directly with the cellular machinery insulin normally uses to open the door for glucose.
From insulin resistance to type 2 diabetes
Insulin resistance, prediabetes and type 2 diabetes exist on a continuum rather than as separate on/off states. Progression through that continuum is common but not automatic — the same trial that established this pathway's clinical significance also showed how effectively it can be interrupted.
The narrowing is deliberate: lifestyle change and, in some cases, medication can interrupt this pathway at almost any point — see Finding 01 below.
How is insulin resistance measured?
There's no single blood-sugar number that directly reads out "insulin resistance." In practice, clinicians and researchers combine a few tools: fasting glucose and fasting insulin together (used to calculate HOMA-IR, a widely used estimate), an oral glucose tolerance test that tracks how blood sugar responds to a standard glucose load, and HbA1c, which reflects average blood glucose over roughly three months. The euglycemic-hyperinsulinemic clamp is considered the research gold standard for directly measuring insulin sensitivity, but it's too resource-intensive for routine clinical use.
What does current research show?
Lifestyle intervention cut progression to type 2 diabetes by 58% in a landmark trial
In the Diabetes Prevention Program, an intensive lifestyle program (targeting 7% weight loss and 150 minutes of weekly activity) reduced progression to type 2 diabetes by 58% compared with placebo over 2.8 years — significantly more effective than metformin, which reduced progression by 31%.
The lifestyle program involved intensive one-on-one coaching well beyond typical clinical care, so real-world programs with less support may not fully replicate these effect sizes.
The benefit persisted for at least 10 years
A 10-year follow-up found diabetes incidence remained 34% lower in the original lifestyle group and 18% lower in the original metformin group, compared with placebo — even though all groups were eventually offered lifestyle support.
The gap between groups narrowed over time as placebo participants also received support, which raises the question of how much earlier intervention timing itself matters.
Continuous glucose monitors mainly help people who already have some glucose dysregulation
Across non-diabetic users, CGM use was linked to a modest reduction in mean blood glucose and better adherence to dietary changes. But splitting the data by group told a sharper story: people with prediabetes saw meaningful glycemic improvement, while people with already-normal blood sugar saw no appreciable benefit.
Most trials were short (12 weeks or less) and paired CGM with structured coaching, making it hard to isolate the device's effect from the coaching itself. The review's authors concluded CGM works best as a feedback tool inside a structured program — not as a standalone fix for people who are already metabolically healthy.
What remains uncertain
- Why do some people become insulin resistant with only modest weight gain, while others with more visceral fat don't?
- In any given person, does the visceral fat come first, or does the insulin resistance drive the fat accumulation — or both, in a loop?
- How much of the Diabetes Prevention Program's effect could realistically be delivered through typical healthcare systems, without trial-level coaching intensity?
- Do glucose-monitoring tools change long-term outcomes for healthy people, or mainly increase short-term awareness that fades once the device comes off?
Interested in metabolic health?
See how we think about formulation science for ingredients relevant to this system — why we chose specific forms, dosages and excipients.
References & Further Reading
- Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
- 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
- Continuous glucose monitoring in non-diabetic populations: a systematic review of observational and interventional studies with meta-analysis.